title: New drugs 04. Part III.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077608:Aprepitant; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D017277:Drug Approval; D004347:Drug Interactions; D016903:Drug Monitoring / Q000451:nursing; D004358:Drug Therapy / Q000451:nursing / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions; D005464:Fluorobenzenes / Q000627:therapeutic use; D005936:Glucans / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D005962:Glucosylceramidase / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000077607:Icodextrin; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D009025:Morpholines / Q000627:therapeutic use; D024802:Nurse's Role; D000069444:Omalizumab; D000077924:Palonosetron; D010353:Patient Education as Topic; D011719:Pyrazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D011812:Quinuclidines / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000932:Antiemetics; D000970:Antineoplastic Agents; D001897:Boronic Acids; D005464:Fluorobenzenes; D005936:Glucans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D007546:Isoquinolines; D009025:Morpholines; D011719:Pyrazines; D011743:Pyrimidines; D011799:Quinazolines; D011812:Quinuclidines; D013449:Sulfonamides; D000077608:Aprepitant; D000077607:Icodextrin; D000069444:Omalizumab; D000077924:Palonosetron; D000069286:Bortezomib; D000068718:Rosuvastatin Calcium; C047638:alfuzosin; D005962:Glucosylceramidase; D005947:Glucose; C119496:tositumomab I-131; C090568:imiglucerase; C472181:efalizumab